The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Cancer Monoclonal Antibodies Market Research Report 2025

Global Cancer Monoclonal Antibodies Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1805292

No of Pages : 71

Ask Your Query

Synopsis

The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.

The global Cancer Monoclonal Antibodies market was valued at US$ 34310 million in 2023 and is anticipated to reach US$ 63810 million by 2030, witnessing a CAGR of 9.2% during the forecast period 2024-2030.

Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.

This report aims to provide a comprehensive presentation of the global market for Cancer Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Monoclonal Antibodies.

Report Scope

The Cancer Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cancer Monoclonal Antibodies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • F. Hoffmann-La Roche
  • Amgen
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals

Segment by Type

  • Murine Antibodies
  • Chimeric and Humanised Antibodies
  • Fully Humanized Antibodies
  • Others

Segment by Application

  • Liver
  • Breast
  • Blood
  • Brain
  • Hodgkins and Non-Hodgkins lymphoma
  • Colorectal
  • Leukaemia
  • Others

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cancer Monoclonal Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cancer Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Index

1 Cancer Monoclonal Antibodies Market Overview
1.1 Product Overview and Scope of Cancer Monoclonal Antibodies
1.2 Cancer Monoclonal Antibodies Segment by Type
1.2.1 Global Cancer Monoclonal Antibodies Market Value Comparison by Type (2024-2030)
1.2.2 Murine Antibodies
1.2.3 Chimeric and Humanised Antibodies
1.2.4 Fully Humanized Antibodies
1.2.5 Others
1.3 Cancer Monoclonal Antibodies Segment by Application
1.3.1 Global Cancer Monoclonal Antibodies Market Value by Application: (2024-2030)
1.3.2 Liver
1.3.3 Breast
1.3.4 Blood
1.3.5 Brain
1.3.6 Hodgkins and Non-Hodgkins lymphoma
1.3.7 Colorectal
1.3.8 Leukaemia
1.3.9 Others
1.4 Global Cancer Monoclonal Antibodies Market Size Estimates and Forecasts
1.4.1 Global Cancer Monoclonal Antibodies Revenue 2019-2030
1.4.2 Global Cancer Monoclonal Antibodies Sales 2019-2030
1.4.3 Global Cancer Monoclonal Antibodies Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Cancer Monoclonal Antibodies Market Competition by Manufacturers
2.1 Global Cancer Monoclonal Antibodies Sales Market Share by Manufacturers (2019-2024)
2.2 Global Cancer Monoclonal Antibodies Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Cancer Monoclonal Antibodies Average Price by Manufacturers (2019-2024)
2.4 Global Cancer Monoclonal Antibodies Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Cancer Monoclonal Antibodies, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cancer Monoclonal Antibodies, Product Type & Application
2.7 Cancer Monoclonal Antibodies Market Competitive Situation and Trends
2.7.1 Cancer Monoclonal Antibodies Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cancer Monoclonal Antibodies Players Market Share by Revenue
2.7.3 Global Cancer Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cancer Monoclonal Antibodies Retrospective Market Scenario by Region
3.1 Global Cancer Monoclonal Antibodies Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Cancer Monoclonal Antibodies Global Cancer Monoclonal Antibodies Sales by Region: 2019-2030
3.2.1 Global Cancer Monoclonal Antibodies Sales by Region: 2019-2024
3.2.2 Global Cancer Monoclonal Antibodies Sales by Region: 2025-2030
3.3 Global Cancer Monoclonal Antibodies Global Cancer Monoclonal Antibodies Revenue by Region: 2019-2030
3.3.1 Global Cancer Monoclonal Antibodies Revenue by Region: 2019-2024
3.3.2 Global Cancer Monoclonal Antibodies Revenue by Region: 2025-2030
3.4 North America Cancer Monoclonal Antibodies Market Facts & Figures by Country
3.4.1 North America Cancer Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Cancer Monoclonal Antibodies Sales by Country (2019-2030)
3.4.3 North America Cancer Monoclonal Antibodies Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Cancer Monoclonal Antibodies Market Facts & Figures by Country
3.5.1 Europe Cancer Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Cancer Monoclonal Antibodies Sales by Country (2019-2030)
3.5.3 Europe Cancer Monoclonal Antibodies Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cancer Monoclonal Antibodies Market Facts & Figures by Country
3.6.1 Asia Pacific Cancer Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Cancer Monoclonal Antibodies Sales by Country (2019-2030)
3.6.3 Asia Pacific Cancer Monoclonal Antibodies Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Cancer Monoclonal Antibodies Market Facts & Figures by Country
3.7.1 Latin America Cancer Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Cancer Monoclonal Antibodies Sales by Country (2019-2030)
3.7.3 Latin America Cancer Monoclonal Antibodies Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cancer Monoclonal Antibodies Market Facts & Figures by Country
3.8.1 Middle East and Africa Cancer Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Cancer Monoclonal Antibodies Sales by Country (2019-2030)
3.8.3 Middle East and Africa Cancer Monoclonal Antibodies Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Cancer Monoclonal Antibodies Sales by Type (2019-2030)
4.1.1 Global Cancer Monoclonal Antibodies Sales by Type (2019-2024)
4.1.2 Global Cancer Monoclonal Antibodies Sales by Type (2025-2030)
4.1.3 Global Cancer Monoclonal Antibodies Sales Market Share by Type (2019-2030)
4.2 Global Cancer Monoclonal Antibodies Revenue by Type (2019-2030)
4.2.1 Global Cancer Monoclonal Antibodies Revenue by Type (2019-2024)
4.2.2 Global Cancer Monoclonal Antibodies Revenue by Type (2025-2030)
4.2.3 Global Cancer Monoclonal Antibodies Revenue Market Share by Type (2019-2030)
4.3 Global Cancer Monoclonal Antibodies Price by Type (2019-2030)
5 Segment by Application
5.1 Global Cancer Monoclonal Antibodies Sales by Application (2019-2030)
5.1.1 Global Cancer Monoclonal Antibodies Sales by Application (2019-2024)
5.1.2 Global Cancer Monoclonal Antibodies Sales by Application (2025-2030)
5.1.3 Global Cancer Monoclonal Antibodies Sales Market Share by Application (2019-2030)
5.2 Global Cancer Monoclonal Antibodies Revenue by Application (2019-2030)
5.2.1 Global Cancer Monoclonal Antibodies Revenue by Application (2019-2024)
5.2.2 Global Cancer Monoclonal Antibodies Revenue by Application (2025-2030)
5.2.3 Global Cancer Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
5.3 Global Cancer Monoclonal Antibodies Price by Application (2019-2030)
6 Key Companies Profiled
6.1 F. Hoffmann-La Roche
6.1.1 F. Hoffmann-La Roche Corporation Information
6.1.2 F. Hoffmann-La Roche Description and Business Overview
6.1.3 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.1.4 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Product Portfolio
6.1.5 F. Hoffmann-La Roche Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Cancer Monoclonal Antibodies Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Bristol-Myers Squibb
6.3.1 Bristol-Myers Squibb Corporation Information
6.3.2 Bristol-Myers Squibb Description and Business Overview
6.3.3 Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Bristol-Myers Squibb Cancer Monoclonal Antibodies Product Portfolio
6.3.5 Bristol-Myers Squibb Recent Developments/Updates
6.4 Takeda Pharmaceuticals
6.4.1 Takeda Pharmaceuticals Corporation Information
6.4.2 Takeda Pharmaceuticals Description and Business Overview
6.4.3 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Product Portfolio
6.4.5 Takeda Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cancer Monoclonal Antibodies Industry Chain Analysis
7.2 Cancer Monoclonal Antibodies Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cancer Monoclonal Antibodies Production Mode & Process
7.4 Cancer Monoclonal Antibodies Sales and Marketing
7.4.1 Cancer Monoclonal Antibodies Sales Channels
7.4.2 Cancer Monoclonal Antibodies Distributors
7.5 Cancer Monoclonal Antibodies Customers
8 Cancer Monoclonal Antibodies Market Dynamics
8.1 Cancer Monoclonal Antibodies Industry Trends
8.2 Cancer Monoclonal Antibodies Market Drivers
8.3 Cancer Monoclonal Antibodies Market Challenges
8.4 Cancer Monoclonal Antibodies Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock